Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1552       

   Table of Contents      
CORRESPONDENCE
Year : 2013  |  Volume : 138  |  Issue : 1  |  Page : 147-148

Authors' response


Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bhubaneswar 751 019, India

Date of Web Publication6-Aug-2013

Correspondence Address:
Prasanta Raghab Mohapatra
Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bhubaneswar 751 019
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

How to cite this article:
Garg K, Mohapatra PR. Authors' response. Indian J Med Res 2013;138:147-8

How to cite this URL:
Garg K, Mohapatra PR. Authors' response. Indian J Med Res [serial online] 2013 [cited 2020 Jan 26];138:147-8. Available from: http://www.ijmr.org.in/text.asp?2013/138/1/147/116206

Sir,

We appreciate Karabay & Gozdas for their interest in our publication [1] and their concern regarding the use of pyrazinamide during pregnancy. This issue has been debated since long despite no evidence on its teratogenicity in humans. By and large its use has been the part of standard regimens in many countries. As of now, the leading international organizations like International Union Against Tuberculosis and Lung Disease (IUATLD), World Health Organization (WHO), British Thoracic Society (BTS), American Thoracic Society (ATS) and Revised National Tuberculosis Control Programme of India (RNTCP) support its use in standard first line regimens for tuberculosis in pregnant women [2],[3] .

Our use in this case was in accordance with the Indian National Guidelines for Tuberculosis in Pregnancy and it is a component of DOTS (Directly Observed Treatment-Short Course) used under RNTCP. In our case, the initial intrauterine growth retardation in foetus by obstetrical ultrasound at presentation could be explained by the disseminated disease process of miliary tuberculosis itself. The use of pyrazinamide in our patient, in combination with other standard first line anti-tubercular drugs did not cause any teratogenic effect in the child as our patient delivered a healthy child at term.

As per WHO, IUATLD and Indian National Guidelines, use of pyrazinamide is safe during pregnancy for treating tuberculosis. We do not have enough evidence to omit this important drug from standardized anti-tubercular regimens for the patients with tuberculosis during pregnancy.

 
   References Top

1.Garg K, Mohapatra PR. A pregnant woman with dyspnoea, fever & decreased vision. Indian J Med Res 2012; 136 : 1062.   Back to cited text no. 1
[PUBMED]    
2.Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy 2012; 2012:379271.doi:10.1155/2012/379271. PubMed PMID:22132339; PubMed Central PMCID: PMC3206367.  Back to cited text no. 2
    
3.Training module for medical practitioners. Revised National Tuberculosis Control Programme (RNTCP). Available from: http://www.tbcindia.nic.in/pdfs/Training%20Module%20for% 20Medical%20Practitioners.pd , accessed on May 12, 2013.  Back to cited text no. 3
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed293    
    Printed10    
    Emailed0    
    PDF Downloaded141    
    Comments [Add]    

Recommend this journal